Explore our comprehensive coverage of senolytics, including scientific research, policy developments, environmental impacts, and solutions for a sustainable future.
The FDA's accelerated approval of systemic senolytics and the NIH's pivot to AI-managed decentralized trials officially retire the legacy Phase III mo...
Read Full Story →![[The Alchemist's Ledger: Five Breakthroughs Signal the End of Symptom-Management Medicine]](https://www.crimaz.com/assets/images/no-image.png)
Medical Research[The simultaneous FDA approvals of a triple-agonist for MASH, in vivo CRISPR for hypercholesterolemi...
FashionThe 2026 convergence of the first Phase 3 in vivo CRISPR trial, FDA AI-enabled clinical trial optimi...
